ResMed Inc. (RMD)
Here's Why You Should Add RMD Stock to Your Portfolio Now
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ResMed CEO On Earnings, Sleep Apnea
ResMed (RMD) CEO Mick Farrell joins Morning Trade Live to discuss the company's latest earnings beat. ResMed primarily focuses on sleep apnea and COPD.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.
ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Low - JPMorgan Saul Hadassin - Barrenjoey Capital Anthony Petrone - Mizuho Daniel Hurren - MST Marquee Mike Matson - Needham & Company Brett Fishbin - KeyBanc Capital Markets Suraj Kalia - Oppenheimer Lyanne Harrison - Bank of America Andrew Paine - CLSA Operator Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago.
ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.
